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COMMENTARY
Absract: This paper overviews the controversies surrounding the abuse of prescription
analgesic OxyContin® (oxycodone hydrochloride; Purdue Pharma, Stamford, CT, USA). It
discusses solutions to this medication-related issue, which has been touted as reaching epidemic
proportions. Relevant literature from 1990 to 2004 was identified through a MEDLINE search,
and a thorough internet-based search was conducted to obtain the latest updates and government
reports. OxyContin became popular as a street drug through its ability to induce a quick heroin-
like euphoria. The media hype surrounding OxyContin abuse and the “black box” warning on
its label may have added to the abuse and diversion. The US Food and Drug Administration
took steps by writing letters to Purdue Pharma, the manufacturers of OxyContin. Purdue Pharma
developed a database to identify OxyContin abusers throughout the nation and also launched
campaigns to educate patients through the internet. Further suggestions to managing the abuse
of OxyContin include: community pharmacists’ assessment of behavioral risk factors that
could lead to patient medication abuse; medication abuse risk management courses for
physicians; development of a national database linking all pharmacies specifically designed
to identify abusers; and tamper-resistant prescription pads for controlled substances, which
seems the most plausible and immediate solution to this problem.
Keywords: OxyContin, abuse, diversion, prescription drug abuse
Introduction
According to a government-funded survey, in 1999, an anticipated 4 million
Americans aged 12 years or older used oral sedatives, stimulants, antipsychotic agents,
or opioids in ways not intended by prescribers (Thompson 2001). A recently available
report from the National Household Survey on Drug Abuse suggests that the use of
prescription drugs in unintended ways is increasing among adolescents and adults
over the age of 60 (Thompson 2001), with
 analgesics getting most of the attention.
Painkiller drugs, especially the opioid analgesics, have a high potential for misuse
and abuse. Some of the branded drugs commonly prescribed for the management of






and Demerol®. The cynosure of attention was Purdue Pharma’s OxyContin (Purdue
Pharma, Stamford, CT, USA), which was approved by the US Food and Drug
Administration (FDA) in 1995 (FDA 2001).
 The active ingredient of OxyContin is
oxycodone, a semisynthetic narcotic analgesic, prescribed for management of
moderate to severe pain, chronic pain syndromes, and terminal cancers. The drug is
formulated to give a sustained release of oxycodone over a period of 12 hours. Tablets
of OxyContin are available in 10-, 20-, 40-, 80-, and 160-mg doses. OxyContin abusers
often chew the tablets, crush them and snort the powder, or dissolve them in water
and inject the drug for a fast high. According to the US Drug Enforcement
Administration (DEA), the prescription painkiller OxyContin may have been involved
in 464 overdose-related deaths in two years (Manesses Communication Group 2002).
The prevalence of lifetime nonmedical users of oxycodone increased from 11.8 million
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in 2002 to 13.7 million in 2003 (US DHHS 2005). The
substantial attention that OxyContin has received is not for
its medical effects, but for its addiction liability and abuse
potential (Inciardi and Goode 2003). Although much of the
talk about OxyContin and its addiction liabilities has been
going on for the past few years, the attention turned into a
media frenzy when Rush Limbaugh, a radio host, admitted
his addiction to the drug on his radio talk show. Soon the
headlines of the newspapers and news channels were flooded
with news on the abuse of OxyContin. News channels aired
special features on the “much talked about” drug.
OxyContin is placed in schedule II of the Controlled
Substances Act of 1970. Its placement in schedule II of the
Act apparently gave a warning to prescribers and patients
using the drug, specifically those who were at a high risk
for abuse, that OxyContin is very effective but not without
the risk of getting addicted. On the package insert,
OxyContin carries a boxed warning that is more commonly
known as the infamous “black box”. This black box warns
users not to use broken tablets, chew, crush, or dissolve the
tablets as it may cause rapid release of the drug and even
bioavailability of a fatal dose. Hence, before the black box
could warn, OxyContin abusers had already found ways to
consolidate its mechanism in order to obtain a fast high.
This commentary overviews the controversies
surrounding the abuse of drugs like OxyContin and
objectively looks at the seriousness of this issue. The media-
frenzy associated with the abuse of OxyContin and gamut
of interactions that occurred between the FDA and Purdue
Pharma LP are discussed. Abuse of prescription drugs like
OxyContin is growing day by day and has been described
as a nationwide problem (Thompson 2001).
 What are the
economic aspects of this abuse problem and the financial
impact on the healthcare system? Solutions to prevent this
drug specific abuse problem are suggested.
Literature review
An extensive literature review was conducted to find
information related to the abuse of prescription drugs like
OxyContin. The MEDLINE database was searched for
relevant information pertaining to OxyContin from January
1, 1990 to February 12, 2005, and a thorough internet-based
search using Google
™ search engine was conducted to obtain
the latest updates. The literature review also included
different governmental groups and news or reports by Drug
Abuse Warning Network (DAWN), National Institute on
Drug Abuse (NIDA), National Household Survey on Drug
Abuse, and Substance Abuse and Mental Health Services
Administration (SAMHSA). The US Department of Health
and Human Services and DEA constituted a considerable
proportion of the literature review. Another key source of
information was the United States General Accounting
Office (GAO) Report of December 2003, which focused on
OxyContin abuse and diversion and efforts to address the
problem.
Breakthrough versus street drug
After its approval by the FDA, OxyContin has been hailed
as the breakthrough drug in the treatment of moderate to
severe pain. It has been heralded as a “miracle drug” as it
allows patients with chronic pain to resume a normal life. It
is also known as the pharmaceutical heroin as it gives a
heroin-like euphoria (US DHHS 2001). Patients with
addiction to narcotic analgesics, often present fake
complaints to physicians and get prescriptions for
OxyContin. The ready availability and efficacy of the drug
for analgesia made it popular with patients. Priced at a
substantially lower amount than heroin, OxyContin was then
recognized as poor man’s heroin. The drug became popular
not only with patients who were genuinely using it for
analgesia, but also with people intending to abuse it. It
became known as hillybilly heroin, Oxy, OC, or OxyCotton,
and transcended from being a miracle drug used for chronic
analgesia to becoming one of the most highly abused drugs.
Being a schedule II drug, OxyContin posed a threat with
regards to its addiction potential. OxyContin abusers took
no time to realize that crushing and injecting or snorting
the powdered drug gave a euphoria similar to that of heroin.
Since then, cases of abuse or overdose-related deaths have
been reportedly increasing.
OxyContin abuse and diversion
Prescriptions for OxyContin can be easily obtained in clinics
by presenting appropriate complaints. Physicians are not
formally trained to identify the drug-seeking behavior of
abusers (US DHHS 2001). Many patients addicted to the
drug often go “doctor-shopping”. This is the term coined to
describe the phenomenon of patients going to different
doctors and obtaining prescriptions for the drug. They also
go to different pharmacies in different areas to get those
prescriptions filled so that they buy the drug unnoticed. To
sustain their habits, OxyContin abusers sometimes engage
in committing fraud and theft (US DHHS 2001), and abusers
will commit forgery and alter prescriptions. Burglaries and
robberies in pharmacies have been reported. Abusers use
the drug in unintended ways by crushing the tablets,Therapeutics and Clinical Risk Management 2005:1(2) 79
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dissolving and injecting, or snorting the powder. In the
process of getting a quick heroin-like high, people put
themselves at risk of overdose-related death. There have
also been case reports of adolescents stealing OxyContin
from their parents (Katz and Hays 2004).
The black box warning on the OxyContin package insert
recommends that patients do not crush the drug as it results
in rapid release of the drug. The warning itself could have
encouraged users to use the drug in a manner that is not
intended. Also partly responsible for OxyContin’s diversion
from being an efficacious and convenient analgesic to being
an addictive drug are physicians who run OxyContin “pill
mills”, thereby increasing the availability and accessibility
of the prescription analgesic and its potential for abuse.
The DEA’s investigation on OxyContin abuse and
diversion reports that the primary sources of diverted
pharmaceuticals are the illegal acts by physicians and even
pharmacists. Some reports allege that physicians have been
creating fraudulent prescriptions to provide a supply of the
drug for distribution purposes (DEA 2002). Although there
has not been any mention about specific data, doctor
shopping remains one of the popular ways of illicitly
obtaining the prescription drug for abuse (DEA 2002).
Robberies, burglaries, and thefts are some of the other
methods of obtaining OxyContin illegally.
A national epidemic or media
frenzy?
News about OxyContin abuse first surfaced in rural areas
of Maine during the late 1990s and then spread down the
east coast to include
 West Virginia, Kentucky, Southern
Ohio. The most hard hit areas were that of the rural
Appalachia and Ohio valley (Inciardi and Goode 2003). Data
suggest that Kentucky was one of the leading states for
OxyContin-related crimes, mostly break-ins (Inciardi and
Goode 2003). There was a tremendous increase in the
number of patients admitted for treatment of narcotic-related
abuse, and the majority of them were being treated for
OxyContin. Many reports of OxyContin abuse appeared in
the local newspapers and television channels; however,
media outlets also reported that the OxyContin abuse
problem was not restricted to the rural Appalachia but was
spreading across the entire United States.
OxyContin abuse-related news began to appear from as
early as 2000. Newspapers ran several features on
OxyContin. The Bangor Daily News spread the information
including the properties of the drug, the mechanism to
compromise the time-release of the drug, tactics used for
diversion, and concerns of the medical profession about the
potential for abuse (Inciardi and Goode 2003). Media
coverage gained more thrust after Kentucky’s “Operation
OxyFest 2001”. Newspaper headlines yelled out different
stories about the miracle drug OxyContin and how it was
abused. Media coverage included stories about robberies,
theft, fraud, pharmacy break-ins, and features of several pill
mill doctors who supported the addiction of their patients
by frequently prescribing the drug. It appeared as if the
OxyContin abuse was transformed from a regional problem
to a national epidemic. OxyContin is just one of the drugs
of the highly abused list of narcotics that people are addicted
to and need more monitoring.
The extensive media coverage and hype made a “villain”
out of OxyContin, and there is a concern that the exclusive
media focus enhanced the popularity of the drug and
contributed towards its abuse.
Economic facets of OxyContin
abuse
The manufacturer of OxyContin, Purdue Pharma LP, was
engrossed in aggressively promoting OxyContin,
specifically for noncancer pain. The drug has been a major
economic success for Purdue Pharma, accounting for almost
80% of the company’s business (Inciardi and Goode 2003).
The
 number of prescriptions and retail sales have been
growing at an enormous rate. According to data by IMS,
the annual number of prescriptions for OxyContin, for
noncancer increased nearly tenfold, from about 670 000 in
1997 to about 6.2 million in 2002, whereas the annual
number of OxyContin prescriptions for cancer-associated
pain grew by fourfold in six years from 250 000 to just over
1 million (Katz and Hays 2004). A DEA report indicated
that more than 7.2 million prescriptions were dispensed in
2002 and approximately 5.8 million prescriptions were for
the single entity product OxyContin. The retail sales of the
drug have skyrocketed ever since its market introduction.
Recent figures for the drug’s retail sales show that there
was a 41% increase in sales from 2000 to 2001, representing
sales worth approximately US$1.45 billion (Inciardi and
Goode 2003). Retail sales of OxyContin reached nearly
US$1.6 billion in 2002 (ABC World News 2003). In dollar
amounts, it is almost the highest in retail sales of brand name
substances.
Medicaid fraud presents an inexpensive way of abusing
OxyContin. A Medicaid patient would pay US$3 for a bottle
of a hundred 80-mg OxyContin tablets (Inciardi and Goode
2003).
 However, in the areas where there is scarcity ofTherapeutics and Clinical Risk Management 2005:1(2) 80
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employment or money, people often sell OxyContin at a
very high street price. OxyContin may be sold at US$1 for
each milligram. This diversion has not only prompted
burglaries in pharmacies but it has also put a high cost of
abuse on its abusers.
FDA takes actions
Ever since the introduction of OxyContin to the market, it
has been the center of attention in the world of chronic pain
management. Popular not for its medicinal properties but
for its potential for abuse, OxyContin (oxycodone)-related
emergency department drug mentions have increased at an
alarming rate from 6429 in 1999 to about 18 409 in 2001
(DEA nd).
 Reports of illegal use, misuse, abuse, and
diversion of OxyContin prompted the FDA to take
immediate actions. The FDA cited Purdue Pharma twice
for using potentially false or misleading medical journal
advertisements for OxyContin, which violated the Food,
Drug and Cosmetic Act 1938. This included one that did
not include warnings about the potentially fatal risks
associated with the drug’s use (US General Accounting
Office 2003).
Purdue Pharma had not submitted an OxyContin
promotional video for review by the FDA at the time of its
initial distribution in 1998, as required by FDA regulations.
The FDA in 2002 viewed one such video and found that the
video minimized the drug’s risks and made unsubstantiated
claims (US General Accounting Office 2003).
The FDA also discovered that the safety warning issued
to patients through the “black box” may have unintentionally
disseminated information that may have led to OxyContin’s
misuse. In July 2001, the FDA reevaluated OxyContin’s
label and made changes to strengthen the “Warnings”
section. The FDA’s most prominent actions were evident
from two letters that it wrote to the manufacturers of the
drug, but this was not before the drug had nearly become a
national crisis.
Purdue Pharma retorts
Purdue Pharma was highly criticized for its aggressive
campaign to promote OxyContin, specifically its targeting
of physicians and its failure to submit the promotional video
to the FDA. The company responded to the FDA’s warnings
and actions by releasing a letter that was addressed to all
healthcare professionals. The letter specified that the
company had revised sections of the prescribing information,
specifically the “Warnings” section, which now included a
new box warning and an “Indications” section. Purdue
Pharma was asked to add a black box warning, which is the
highest level of warning the FDA can place on an approved
drug product.
To combat criticism, Purdue Pharma distributed more
than 400 000 brochures on diversion prevention to
pharmacists and healthcare professionals and started a pilot
program in Maine and Virginia involving free tamper-
resistant prescription pads for physicians (Thompson 2001).
Purdue Pharma submitted its risk management plan to the
FDA in August 2001. The plan included actions such as
strengthening the safety warning on the label, training
Purdue Pharma’s sales force on the revised label, conducting
comprehensive education programs for healthcare
professionals, and developing a national database for
identifying and monitoring the abuse and diversion of
OxyContin.
Purdue Pharma also developed the Researched Abuse,
Diversion, and Addiction-Related Surveillance (RADARS)
system, as part of its risk management plan, to study the
nature and extent of abuse of OxyContin and other schedule
II and III prescription medications and implement
interventions to reduce abuse and diversion (US General
Accounting Office 2003).
 RADARS collects and computes
abuse, diversion, and addiction rates for certain drugs based
on population, and determines national and local trends. As
one of the recent efforts to thwart the abuse and misuse of
prescription drugs like OxyContin, Purdue Pharma LP, has
funded an information clearinghouse for data related to
pharmacy thefts called RxPATROL
™ (Pattern Analysis
Tracking Robberies and Other Losses). RxPATROL is a
collaborative initiative between industry, different pharmacy
organizations, and law enforcement to gather, assemble,
analyze, and disseminate pharmacy theft intelligence to law
enforcement throughout the nation. Purdue Pharma directed
its sales representatives to begin using 11 indicators to
identify possible abuse and diversion and to report the
incidents to Purdue Pharma’s General Counsel’s Office for
investigation. As of September 2003, through its own
investigations, Purdue Pharma had identified 39 physicians
and other healthcare professionals whom they referred to
legal, medical, or regulatory authorities for further action
(US General Accounting Office 2003).
 Purdue Pharma
has also disseminated pain-related information to
consumers through websites, and it also sponsorsTherapeutics and Clinical Risk Management 2005:1(2) 81
OxyContin abuse
painfullyobvious.com, which discusses the dangers of
abusing prescription drugs.
DEA also on guard
In response to the growing concern among the local, state,
and federal officials about the abuse, illicit use, misuse, and
diversion of OxyContin, the DEA has launched a
comprehensive effort to prevent this diversion and abuse.
Officials in Kentucky are utilizing a new and efficient tool
called KASPER (Kentucky All-Schedule Prescription
Electronic Reporting), which is a database of all controlled
substances dispensed by Kentucky pharmacists (DEA nd).
The action plan has four steps (DEA nd):
1. Enforcement and intelligence. Operations are coordinated
to target the individuals and organizations that are
involved in abuse or diversion, illegal sale, pharmacy
theft, and fraud related to OxyContin.
2. Regulatory and administrative. Authority is utilized to
prevent problems. This involves working closely with
the FDA and urging the rapid reformulation of
OxyContin to an extent that is technically possible.
3. Seeking industry cooperation. The cooperation of
Purdue Pharma is sought to make the program a success.
4. Awareness/education/outreach initiatives. Outreach
efforts to educate the public, schools, healthcare industry,
and state and local governments on the risks associated
with OxyContin are implemented.
Discussion
The findings of this investigation bring up several issues.
The use of opioids in pain management has always been an
area of debate and of course a lot of concern. But what makes
the OxyContin issue so special? The problem lies not only
in the specific medication, but in the increasing base rate of
addiction in the US and various means of availability of
this medication (Passik 2001). Many factors may have
contributed to the abuse potential and diversion of
OxyContin. The warning on OxyContin’s label may have
been misleading and inadvertently provoked the nonmedical
usage of the drug. To purport their addiction, abusers of
OxyContin found out ways to compromise its time-release
and certainly different ways to obtain it. Oxycodone being
a water soluble ingredient, readily dissolves in water. This
property could have provoked abusers to inject a solution
of crushed OxyContin tablets to obtain a quick high.
Increases in OxyContin-related crime rates can be attributed
to the increasing number of abusers. Many reports of
OxyContin abuse have occurred in rural areas with labor-
intensive industries. These industries are often located in
economically backward areas. People living in these areas
may have been tempted to sell their legitimate prescriptions
for profit (Hays 2004). In addition, OxyContin prescriptions
are expensive. The generic manufacturing of OxyContin will
not begin before the patent expiration of OxyContin in about
2012 (since it was approved in 1995). With a street price of
nearly US$1.00 per milligram of OxyContin, drug price
remains a risk factor for crime related to obtaining the
medication. The all-embracing exclusive media coverage
and headlines sensationalizing OxyContin abuse also could
have added fuel to the fire, but could also have prompted
the drug regulating agencies to exercise strict control over
controlled prescription substances and also take actions to
curb the ongoing abuse.
Purdue Pharma’s aggressive promotion of the drug and
targeting physicians to increase prescribing and hence sales
was received with a lot of criticism. Purdue Pharma was
heavily censured for the abuse of OxyContin. On the other
hand, the FDA did take mandatory actions against the drug
and issued warnings to its manufacturers only after the
problem became deep-rooted. Purdue Pharma also took
major steps to prevent the abuse and diversion of the drug.
In its effort to prevent the OxyContin abuse, Purdue Pharma
took steps in every possible direction including addressing
healthcare professionals regarding the safe use of Oxy-
Contin, strengthening the black box warning, distributing
brochures, developing a risk management plan, developing
a national database, and also arresting pill mill doctors.
According to their new plan, the FDA, since September
2004, now mandates the drug manufacturers to submit a
risk management plan to deal with drug abuse/diversion to
obtain the drug approval. Even for the generic manufacturers
of the drug, this is a requirement. Preparing beforehand for
an expected potential problem such as medication abuse
seems to be an important solution to the very problem itself
(US General Accounting Office 2003).
Although OxyContin has been abused in many instances,
there remain many patients who genuinely use or want to
use OxyContin for its medicinal properties, and these
patients should not remain untreated. Patients who are in
need of the drug are finding it difficult to obtain. Given the
controversy, everyone who seems to be using OxyContin
could be suspected of abusing it. Pharmacies in some areasTherapeutics and Clinical Risk Management 2005:1(2) 82
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had stopped carrying OxyContin due to the fear of robberies
(Suleman 2002). Patients who had legitimate prescriptions
for OxyContin have not been able to obtain the medication
on time, and Medicaid patients in several states in the US,
namely Florida, Maine, Ohio, South Carolina, and West
Virginia, now require prior authorization for OxyContin
(Suleman et al 2002).
 Actions have been taken. Steps have
been enforced. But it will take time before this problem
mitigates and does not pose a problem to the availability of
OxyContin to genuine patients.
Looking at this catastrophe from a pharmacists’
perspective affords some insight into preventing a similar
situation. In our opinion, the answer lies in educating
healthcare providers in addiction and the careful assessment
of patients (Passik 2001). Special attention needs to be given
to patients’ psychological, social, and the many factors that
could lead to the risk of abuse. Patients with a history of
substance abuse need more focused care, regular and
frequent monitoring, and reassessment. There is a shortage
of settings that can treat pain and provide an appropriate
structure (Passik 2001), whereby the patient’s substance
abuse history and risk of addiction is carefully assessed and
the drug prescribed appropriately. The major players in the
community of pain management must address this issue with
concern, reason, and education.
A national database linking all pharmacies that is
specifically designed to identify abusers can be developed.
Community pharmacists can also play a major role in the
uprooting of this problem. With the proper assessment of
patients and extended counseling sessions, pharmacists can
watch out for behavioral factors that might contribute to a
potential abuse problem. If necessary, pharmacists should
also communicate with the prescribers before dispensing
such medication to patients who have a history of illegitimate
use and abuse. Physicians could also be educated and
encouraged by various physician organizations to undergo
specific CME courses addressing issues of risk management
for controlled medications. The pharmaceutical industry and
various state and federal regulatory agencies should be
encouraged to provide the necessary resources for such
interventions. The Internet is a good source of dissemination
of information about OxyContin, its harmful effects, how
to avoid abuse, and how to manage chronic pain.
Government and professional organizations also need to
accept their share of the responsibility for advocacy,
continuing education, and increasing pharmacists’ involve-
ment in preventing OxyContin abuse (Cobaugh 2003).
One of the most rational solutions to such a problem
would be using tamper-resistant prescription pads for
OxyContin. Counterfeit-resistant prescription pads provide
prescribers with a rational solution to the growing problem
of prescription forgery and prescription drug abuse (see
http://www.rxsecurity.com/index.php) (Partners Against
Pain 2001).
 Such prescription pads have copy-resistant
background and an individual numeric identifier for each
order. When copied, “VOID” appears on the photocopy and
tamper-resistant ink shows an attempt to alter the script.
Use of such pads would make it nearly impossible to fake
prescriptions and the state of Texas in the US encourages
their use for controlled substances. It seems most reasonable
that the nearest and quickest solution to contain this threat
of abuse is using such pads all across the nation.
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